Boothbay Fund Management’s DiaMedica Therapeutics DMAC Stock Holding History

Boothbay Fund Management’s Portfolio DMAC Stock Details DMAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-20,603	Closed	-$52K	–	2341
2022 Q1	$52K	Hold	20,603	–	–	﹤0.01%	2174
2021 Q4	$77K	Sell	20,603 -10,301	-33%	-$40.4K	﹤0.01%	1743
2021 Q3	$124K	Sell	30,904 -15,658	-34%	-$59.9K	﹤0.01%	1757
2021 Q2	$207K	Hold	46,562	–	–	0.01%	1507
2021 Q1	$426K	Hold	46,562	–	–	0.02%	1020
2020 Q4	$472K	Hold	46,562	–	–	0.02%	776
2020 Q3	$197K	Buy	+46,562	New	+$246K	0.01%	949

Other funds holding DMAC

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

CLG

Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JAMONY

Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Boothbay Fund Management's DMAC Position: Q2 2022 in Review

Boothbay Fund Management sold out of DiaMedica Therapeutics (DMAC) in Q2 2022, closing a stake of 20,603 shares — an estimated $52K sold.

Boothbay Fund Management first reported a position in DMAC in Q3 2020 and held it in 7 quarters. The position peaked at $472K in Q4 2020. 28 funds tracked by Wall St. Rank hold DMAC as of Q2 2022.

Boothbay Fund Management reported no remaining DiaMedica Therapeutics position as of Q2 2022 after selling out during the quarter.
Boothbay Fund Management sold 20,603 DiaMedica Therapeutics shares in Q2 2022, an estimated $52K.
Boothbay Fund Management first reported a position in DiaMedica Therapeutics in Q3 2020 and held it in 7 quarters.
Boothbay Fund Management's DiaMedica Therapeutics position peaked at $472K in Q4 2020.
28 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2022.

Based on Boothbay Fund Management's 13F filing for Q2 2022, filed 15 Aug 2022.